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Can Observational Studies Approximate RCTs?“It is the position of this Task Force that rigorous well designed
and well executed Observational Studies (OS) can provide evi-
dence of causal relationships” [1]. All flows from this carefully
crafted statement in the middle of the ISPOR Good Research
Practices Task Force Report, which provides a well-reasoned
and well-conceived summary of the potential role in compara-
tive effectiveness research (CER) of observational studies, and
especially of prospective studies— ones that collect informa-
tion. But the conceptual basis for the value of OS and the prin-
ciples articulated would lack compelling interest if fulfilling the
goals of CER did not force us to make use of OS, and, in doing so,
bring OS as close to parity as possible with randomized con-
trolled trials (RCTs).
The implication of this task force review article is that the
question of RCTs versus OS should be reframed: Can conclu-
sions from OS studies, if optimized (“rigorous, well-designed
and well-executed”), be used, at approximately the same level
of the hierarchy of quality, hopefully in conjunction with RCTs,
in systematic reviews to inform clinical practice guidelines and
policymakers about the effectiveness of medical practices.
In theory, few would argue that RCTs can establish causal
relationships where OS cannot, but in clinical trials research the
well-known drawbacks and flaws of RCTs, especially in CER,
may cause us to pause in rating them higher than well-done OS,
as aspired to in the creation of this report. Of course, disagree-
ment will continue as to whether causal inferences can be
drawn from OS with sufficient confidence to support either clin-
ical or policy decisions. The potential problems with OS for CER
are certainly greater than for OS of comparative safety, because
of the greater likelihood of important selection biases. Yet, OS
for comparative safety are still often discounted; despite multi-
ple observational studies showing that rofecoxib increased the
risk of acute myocardial infarction, the major stimulus to
change was an RCT [2]. Thus, we need guidance such as this
report’s to articulate standards around which we can try to
achieve a consensus.
The key, therefore, lies in the phrase “rigorous well-designed
and well-executed,” and this article provides an outline of the ma-
jor determinants of high quality in crafting OS. We will summarize
them below, but it deserves noting that, in past research, when
neither RCTs nor OS were necessarily optimized, comparison of
OS to RCTs revealed that there is a great deal of correspondence
between the two [3]. Several major reviews comparing OS and
RCTs have concluded that the results are similar [3–5] in a surpris-
ing percentage of studies of the same topic. Even in the often-
quoted Women’s Health Institute, as noted in the ISPOR report,
when observational hormone replacement treatment data were
analyzed only for treatment initiators, the results were essentially
the same as in the random trial data, which itself enrolled only
previously untreated patients [1]. In this case, the emphasis is on
the subgroup of long-term versus naive users, rather than the
more general topic of heterogeneity of treatment effects in varyingsubsets of patients with the same medical conditions. If OS were
well conceived and well performed on a relatively homogeneous
sample of patients, however, the persuasiveness of the results
might be very high, especially in light of those problems increas-
ingly found in RCTs: crossover, attrition, nonadherence, and vary-
ing quality of the sites and providers (or varying fidelity to an
intervention), all of which serve to diminish the internal validity of
the RCT.
Generally, it is a given that even in large pragmatic trials, OS
can include a wider range of patients and can address rare events
harms and multiple outcomes better than do RCTs. But the most
contentious issue remains the internal validity. To elevate the
level of internal validity, the task force makes a series of recom-
mendations designed to bring the internal validity of OS closer and
closer to that of RCTs.
First, the strength of prevailing opinion, the need for large sam-
ple sizes (as for harms), the value of studying multiple outcomes,
the difficulties (adherence, crossovers, switching treatments, and
time-varying covariates) encountered if randomization is contem-
plated, the need for early and highly generalizable answers—all
these factors should be weighed both in deciding to perform an OS
and in its design and conduct. Second is the unambiguous speci-
fication of the research question and the population to which po-
tentially casual inferences can be aimed. They emphasize the no-
tion of testing a hypothesis, as done in RCTs. The design issues
and strategies to enhance the causal inferences are intended to
have the OS approximate an RCT.
Given the potential for achieving this level of approximation
after application of the strategies proposed by the task force, the
credibility of the results of an optimal OS must then be balanced by
the well-known and increasing flaws and drawbacks of RCTs, in-
cluding not only the issues mentioned earlier but also the increas-
ing problem of better “usual care” (sometimes called secular
trends) and the problem of the average effect not revealing the
often vastly different results of different subgroups within the
same diagnosis [6–8].
The authors sensibly recommend such strategies as increas-
ing the number of comparators, of examining outcomes that are
not directly affected by the intervention, of prospectively in-
cluding all the potential cofounders, and on focusing on the
highest priority comparisons where there are multiple treat-
ments. They also address confounders and bias, first by recog-
nizing the biases and second by recommending strategies to
deal with them: understanding the practice patterns that in-
duce bias; distinguishing inception from already treated co-
horts; using statistical approaches to better balance groups
(propensity scores, instrument variables). They wisely point out
[1] that the “absence of treatment heterogeneity is a crucial
assumption for virtually all analytical approaches,” the kind of
statement that is not often heard in the disputes over study
designs. They also give tips on sample size determination with
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but increasing awareness of the problems.
Perhaps the guidance’s most important contribution is its fo-
cus on the ability to improve the validity of OS by prospectively
collecting data that would otherwise be unavailable. Examples in-
clude quality-of-life data, information about medical history, or
measures such as pulmonary function testing that may be missing
or performed with unacceptable variability.
Finally, they focus on execution, where the practical issues
may lead to matching or stratification either on the basis of a
propensity score or, as some have suggested, on the basis of a
prespecified and prestudied clinical variable, hopefully reduced by
a multivariate composite [6–9]. This task force report is full of
pearls” and tips for the wise. It is also balanced and goes out of
ts way not to polarize the contentious debate between RCTs
nd OS. The concrete tips and the balanced tone encourage the
eaders to be as thoughtful as possible about the choice of an
S, emphasizing the notion that OS can be viewed as RCTs with-
ut randomization and that RCTs are OS once the randomiza-
ion is complete. That kind of thinking moves us to go beyond
he rigid definitions and hierarchies of designs and think about
nferences, about how systematic review groups will rate the
esearch, how clinical practice guidelines groups will use the
esearch, and how CER can flourish and accomplish its goals.
This is such a fine achievement that criticism seems petty,
ut several directions for the future may be advised. One is to
efine the “strength” of preferences (strength of opinions) such
hat the choice of design will be easier. Another is to more di-
ectly address the problems of subgroups, how to decide
hether to exclude them for other researchers to study, or to
nclude them by matching or stratification, another is to seek
ays in which both RCTs and OS can be undertaken simultane-
usly or in parallel, using similar or overlapping variables, in-
erventions, outcomes, and covariates, so that conclusions can
e drawn as were done belatedly in the Women’s Health Insti-
ute and were attempted in the recent study of patent foramen
vales [5]. Because collection of new data and some of the rec-
mmendations impose substantial costs, it will also be helpful
o have guidance about when these features are truly necessary.
ecause CER resources are constrained, we need all the advice
e can get about allocating them wisely.Sheldon Greenfield, MD
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